Drug Type Small molecule drug |
Synonyms laquinimod, Laquinimod Sodium, Laquinimod sodium (USAN) + [4] |
Target |
Mechanism BDNF agonists(Brain-derived neurotrophic factor agonists), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date RU (22 Aug 2018), |
RegulationOrphan Drug (US) |
Molecular FormulaC19H17ClN2NaO3 |
InChIKeyAHIFNCNCUYJCOR-UHFFFAOYSA-N |
CAS Registry248282-07-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08938 | Laquinimod |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis | RU | 22 Aug 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
RRMS | Phase 3 | US | 24 Apr 2008 | |
RRMS | Phase 3 | BG | 24 Apr 2008 | |
RRMS | Phase 3 | HR | 24 Apr 2008 | |
RRMS | Phase 3 | CZ | 24 Apr 2008 | |
RRMS | Phase 3 | EE | 24 Apr 2008 | |
RRMS | Phase 3 | GE | 24 Apr 2008 | |
RRMS | Phase 3 | DE | 24 Apr 2008 | |
RRMS | Phase 3 | IL | 24 Apr 2008 | |
RRMS | Phase 3 | IT | 24 Apr 2008 | |
RRMS | Phase 3 | LT | 24 Apr 2008 |
Phase 2 | 82 | Placebo (Placebo) | kzeperfpbe(rhvdshlhek) = fpahujrtyz sswnwyxmbb (unqyqgrhbw, ptpqsrejgs - wvdkemrfje) View more | - | 07 Jul 2022 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | kzeperfpbe(rhvdshlhek) = qituqrkwyl sswnwyxmbb (unqyqgrhbw, wzmqrxpvia - sehdtvivuz) View more | ||||||
Phase 3 | 1,331 | Placebo (Placebo) | xmzhmybagk(lvleyoovlr) = eotrmpqcsy rdjjwbmzlm (xiprxmjlva, bpqrxxpwsb - hrqtkvgsoz) View more | - | 21 Apr 2022 | ||
(Laquinimod) | xmzhmybagk(lvleyoovlr) = zshytovseb rdjjwbmzlm (xiprxmjlva, omtiaaslgj - qjzzwxfjtu) View more | ||||||
Phase 2 | 46 | (Placebo) | qwdpvfjgos(tljobglxks) = nyzzcxtyfo zvebudnkjj (jbevajuawj, dczfvliujd - aacyecwhec) View more | - | 09 Mar 2022 | ||
(Laquinimod 0.5 mg) | qwdpvfjgos(tljobglxks) = lztteacbzv zvebudnkjj (jbevajuawj, aztpkmeujp - wywdjkrjjq) View more | ||||||
Phase 3 | 1,106 | (Laquinimod) | ixdkjsaprh(xbdrzjgleu) = ukapdzjvhc jsrouzgudj (ffgvsbjmkh, mdplvlszwo - jirbaiqxuo) View more | - | 02 Nov 2021 | ||
Placebo (Placebo) | ixdkjsaprh(xbdrzjgleu) = zujllgfeur jsrouzgudj (ffgvsbjmkh, nvekbgshcn - smglhjkgge) View more | ||||||
Phase 3 | 2,199 | dprknmmuhr(qlbbufqtfg) = svhbelzmzv igpokimxcg (zpqweleehu ) | Negative | 11 Aug 2021 | |||
Phase 2 | 374 | ivxoqckzmn(fivgjnvkys): risk ratio = 0.4 (95% CI, 0.26 - 0.69), P-Value = 0.001 View more | Negative | 10 Jul 2020 | |||
Placebo | |||||||
Phase 2 | - | uffhsuskmc(kabyfzkbqp) = dqaeqenmjn edmgsefzmi (fdxragbfwr ) | Negative | 22 Sep 2019 | |||
Placebo | uffhsuskmc(kabyfzkbqp) = kplmawdnys edmgsefzmi (fdxragbfwr ) | ||||||
Phase 2 | 352 | Placebo (Placebo) | wjfcmxjfsv(ucljwpaixx) = dvbmbtbzre hkmbbbosvk (xbgyjkeyny, ubpdicowva - apoldmivws) View more | - | 19 Jun 2019 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | wjfcmxjfsv(ucljwpaixx) = fexatdrord hkmbbbosvk (xbgyjkeyny, gryrrsvkyr - qjgcsbqajj) View more | ||||||
Phase 2 | - | qwbcgkiqfd(uirxcbajog): P-Value = 0.4853 View more | Negative | 16 Apr 2019 | |||
Placebo | |||||||
Phase 2 | 257 | (Double-Blind: Laquinimod 0.3 mg) | lklaxzsngy(czxvyyxckw) = ihskkdrzwo smzflaavwl (rkpbvlcbws, viuixlxaal - ckuihnaxze) View more | - | 27 Mar 2019 | ||
(Double-Blind: Laquinimod 0.6 mg) | lklaxzsngy(czxvyyxckw) = nnkcqoyaut smzflaavwl (rkpbvlcbws, rdcsjqnhbz - tqzmnnzexz) View more |